Fei Ma

Single-cell analyses reveal key immune cell subsets associated with response to PD-L1 blockade in triple-negative breast cancer

Yuanyuan Zhang, Hongyan Chen, Hongnan Mo et al. · Cancer Cell · 2021 · 786 citations · Full text

Life Sciences, Immunology, Oncology +17

Pyrotinib plus capecitabine versus lapatinib plus capecitabine for the treatment of HER2-positive metastatic breast cancer (PHOEBE): a multicentre, open-label, randomised, controlled, phase 3 trial

Binghe Xu, Min Yan, Fei Ma et al. · The Lancet Oncology · 2021 · 393 citations

Medicine, Oncology, Pharmacology +16

Pyrotinib or Lapatinib Combined With Capecitabine in HER2–Positive Metastatic Breast Cancer With Prior Taxanes, Anthracyclines, and/or Trastuzumab: A Randomized, Phase II Study

Fei Ma, Quchang Ouyang, Wěi Li et al. · Journal of Clinical Oncology · 2019 · 345 citations

Medicine, Oncology, Pharmacology +17

Extensive pathogenicity of mitochondrial heteroplasmy in healthy human individuals

Kaixiong Ye, Jian Lü, Fei Ma et al. · Proceedings of the National Academy of Sciences · 2014 · 318 citations · Full text

Life Sciences, Genetics, Molecular Genetics +14

Phase I Study and Biomarker Analysis of Pyrotinib, a Novel Irreversible Pan-ErbB Receptor Tyrosine Kinase Inhibitor, in Patients With Human Epidermal Growth Factor Receptor 2–Positive Metastatic Breast Cancer

Fei Ma, Qiao Li, Shanshan Chen et al. · Journal of Clinical Oncology · 2017 · 234 citations

Medicine, Oncology, Pharmacology +17